The second nuclear ER, ERβ, which has been suggested to act as partial ERα antagonist and tumor suppressor both in an ERα-dependent and -independent manner, was reported to be less frequently expressed in BRCA1-associated BC (42%) than in sporadic BC (55%), which might contribute to the elevated BC risk in mutation carriers [48]. Here, BRCA1 is linked to breast cancer.